Cantor Fitzgerald Predicts Sanara MedTech FY2025 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Sanara MedTech in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of ($1.09) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.28. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The company had revenue of $21.67 million during the quarter. During the same quarter last year, the company posted ($0.13) earnings per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Sanara MedTech in a research report on Thursday.

Sanara MedTech Stock Performance

Shares of SMTI stock opened at $38.12 on Thursday. The business’s 50-day moving average price is $34.66 and its 200-day moving average price is $32.84. Sanara MedTech has a 12 month low of $26.00 and a 12 month high of $40.75. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $333.17 million, a price-to-earnings ratio of -38.51 and a beta of 1.55.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SMTI. Fifth Third Bancorp acquired a new stake in shares of Sanara MedTech in the fourth quarter valued at about $898,000. JPMorgan Chase & Co. increased its position in Sanara MedTech by 127.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after purchasing an additional 2,272 shares during the period. Barclays PLC raised its holdings in Sanara MedTech by 323.0% during the 3rd quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after purchasing an additional 4,376 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Sanara MedTech by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after purchasing an additional 3,755 shares during the period. Finally, State Street Corp boosted its stake in shares of Sanara MedTech by 9.2% in the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after purchasing an additional 4,932 shares during the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.